抗结核药物的研究进展  

Advances in the research of anti-tuberculosis drugs

作　　者：韦媛媛 杨帆 汤杰 于丽芳 WEI Yuanyuan;YANG Fan;TANG Jie;YU Lifang(Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development,School of Chemistry and Molecular Engineering,East China Normal University,Shanghai 200062,China)

机构地区：[1]华东师范大学化学与分子工程学院,上海分子治疗与新药创制工程技术研究中心,上海200062

出　　处：《中国药科大学学报》2020年第2期231-239,共9页Journal of China Pharmaceutical University

基　　金：国家自然科学基金资助项目(No.21778019)。

摘　　要：随着结核病耐药频率不断升高,结核病治疗面临严峻的挑战,因此,研发新型抗结核药物显得尤为重要。在过去十年中,抗结核药物的研发取得了重要进展。本文将对近年来被批准用于临床和正在进行临床试验的新化学实体按靶点进行分类,并综述其作用机制、体内外药理活性、药代动力学性质以及临床研究结果。对抗结核药物的研发进行了展望,以期对结核病药物研发提供参考。Tuberculosis(TB)treatment is currently falling into a gigantic dilemma-particularly with the increased frequentcy TB resistance,so the development of new anti-tuberculosis drugs is imperative and has received extensive attention.In the past decade,significant progress has been made in this field.Bedaquiline,delamanid and pretomanid have been approved for the clinical use.In addition,many other drugs and combination protocols are undergoing clinical trials.This review focuses on the new chemical entities for TB treatments from multiple perspectives,including the mechanisms of action,in vitro and in vivo pharmacological activities,pharmacokinetic properties and clinical results.Anti-tuberculosis drug research is prospected to provide a reference for drug deve-lopment.

关 键 词：抗结核药物 新化学实体 作用机制 临床研究 进展 

分 类 号：R978[医药卫生—药品]